ALK and lung adenocarcinoma: In our previous studies [23, 24], a PET/CT radiomics model was developed to predict epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement status in lung adenocarcinoma.